Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
People are realizing the delta variant is the beginning of a new pandemic and GeneThera technology may have a shot at controlling it by doing massive waste water testing
They just filed the 10k 2020
I got the feeling that something really big is coming
And you will be their first customer
You are speaking out of shear ignorance!!!
If you understand how coronaviruses work you would never make these comments
This is just market hype!!! what the hell really mean that the vaccine is 99% or 94%specific?
It really means nothing other than is a match with the virus. But what strain? There are now more than 14 strains of the virus that weren’t there when these companies started working on the vaccine.
It took 40 years to improve influenza vaccine and we can get at the best 60% and now in less than 8 months we have a vaccine for coronavirus 99% specific??
And no one so far have seen the raw data??? One big red flag after another
Maybe you can ask the company.
Just found out GTHR is active on Twitter
@GenetheraI something is going down
We have not been able to develop a single vaccine for coronaviruses for human or animals ever. Now here comes Novovax and a bunch of other companies making everybody believe they will have a SARS-2 vaccine by the end of the year. Anybody with any science background knows that this is a bunch of bs!! Stock at $ 150! That is what everybody cares while more people get infected and die! We really lost any sense of decency!!!
Look! you guys can do whatever with your money! But I can tell you something is not right with Zynex. This stock is a dog with a lot of fleas. They spend little or no money in R&D( check Zynex SEC files) they make money by selling batteries and cables come on!!!! You guys are in total denial. Like UFO says: good luck and watch your “6”
The Fed shut down a couple of Zynex competitors because they were doing similar things
Let’s see what happens!
Regardless if they short the stocks the fact is the Zynex is committing Medicare fraud by selling retail available batteries and supply at more than 90% markup. That is price gauging and it is pure and simple illegal. I am sure the Feds will investigate. That is not a first for Zynex as some people probably remember!!!
I do believe he is the one manipulating the stocks
IMO there is some heavy duty manipulation of this stock!!!!
I Am A Bearish Bull On Zynex; It's Complicated https://seekingalpha.com/article/4274713-bearish-bull-zynex-complicated
I guess the new CEO does a better job in convincing the market that Chipotle is less shit that it really is. Nevertheless Chipotle truly is a piece of shit!!!
What the hell all of you were expecting!!!!
Everybody should have run when finding out Barry Honig was into this stock!!! He is a real scumbag. The SEC has been after him for years!
Another Barry Honig scam pump and dump!!!!
You sure did!!!!
Chipotle: Absolutely shit!!!
The only drug that would make a difference for RDHL is RHB104 period!!
Toddski
You are absolute right!!!
The combo therapy is working better that anything available on the market e.g Humera!
Finally a clinical protocol that is proving MAP involvement in CD and other immune deficiency diseases.
I do believe this should finally show the clear link between MAP and CD after years of controversy mostly cause by the disastrous Selby trial which was rigged to begin with!
RBH 104 will be approved by the FDA because causes the disease to go into remission better than any other treatment. Granted that only a MAP vaccine will definitively cure CD, RHB 104 is the next best thing. If RedHill had a blood test (which they do no)to correlate MAP infectious copy numbers with patients in different stages of treatment I do believe the trial could have an early termination.
There is no doubt that MAP causes CD and other immune deficiency diseases. However dairy companies like Nestle have being ferociously lobbing governments to do nothing. consumers have no clue about the problem;most people including physicians do not know what the hell MAP is. This is nothing short of a well planned conspiracy. Everybody in the area of MAP research knows what is going. I have no doubt that the FDA is going to put up a fight to delay or avoid approval of RHB 104. In the meantime over 10% of milk and 50% of infant formula is contaminated with MAP. CD and Type 1 diabetes are the fastest growing diseases in children.
IS ANYBODY GOING TO STOP THESE THIEVES AND SCUMBAGS LUNDY AND MCGONEGAL!!!!!!!!
THE SEC NEEDS TO INVESTIGATE THIS TRANSACTION
Current Report Filing (8-k)
Source: Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) September 21, 2016
Venaxis, Inc.
( Exact name of Registrant as specified in its charter)
Colorado
001-33675
84-155337
(State or other jurisdiction of incorporation or organization)
(Commission File Number)
(I.R.S. Employer Identification No.)
1585 South Perry Street
Castle Rock, Colorado
80104
(Address of principal executive offices)
(Zip Code)
Registrant's telephone number, including area code:
(303) 794-2000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
? Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
? Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
? Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
? Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
As previously announced by Venaxis, Inc., a Colorado corporation (the "Company"), in May 2015 the Compensation Committee (the "Committee") of the Board of Directors (the "Board"), and the Board, approved a retention program for Stephen Lundy and Jeffrey McGonegal, the Company's named executive officers. The Compensation Committee and the Board, in approving such retention program, focused on the importance of and need to retain the services of such named executive officers in pursuing alternative corporate transactions for the Company. Such retention program included a retention bonus, equal to 50% of base salary to be paid to each such named executive officer in connection with the consummation of a corporate transaction . On September 21, 2016, following the closing of the acquisition of BiOptix Diagnostics, Inc., the Compensation Committee and the Board approved payment of the retention bonuses. The aggregate retention bonuses approved equaled $327,265.
Also on September 21, 2016, the Board determined that Richard J. Whitcomb, the Company's Senior Vice President, Corporate Development was an executive officer of the Company. Mr. Whitcomb was the former chief executive officer of BiOptix Diagnostics, Inc., prior to its acquisition by the Company on September 12, 2016. On September 15, 2016, the Company entered into an offer letter of employment with Mr. Whitcomb, providing him with a new hire bonus of $25,000, base salary of $245,000 per year, eligibility to participate in the Company's incentive bonus plan and equity incentive plan, and a new hire stock option grant to acquire 35,000 shares of the Company's common stock with a two-year vesting period, an exercise price equal to the closing price on the date of grant and a ten-year term. The stock option grant was made outside of the Company's 2002 Stock Incentive Plan, as amended, as a new hire award. Under the offer letter, Mr. Whitcomb is entitled to receive certain severance benefits if his employment is terminated by the Company without cause.
The foregoing description of Mr. Whitcomb's employment arrangement is a summary only. The offer letter is attached to this Form 8-K as an exhibit and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
The following exhibit is filed herewith:
Exhibit No.
Document
10.1
Offer Letter, dated September 15, 2016, to Richard J. Whitcomb.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Venaxis, Inc.
By:
/s/ Jeffrey McGonegal
Name:
Jeffrey McGonegal
Title:
Chief Financial Officer
Date: September 27, 2016
EXHIBIT INDEX
Exhibit No.
Document
10.1
Offer Letter, dated September 15, 2016, to Richard J. Whitcomb.
Aytu entered into a line of credit agreement with scammers and Pump and Dump experts Lincoln Capital
Expect the stocks down to 2 pennies
Where is RedHill in the development of MAP blood test for RHB 104????
RHB 104 will not get FDA approval until the company will have a viable MAP blood assay to evaluate patients response to MAP therapy. That is the reason why they need extensive Phase III. They are quite a way to get a blood test.
Dead and buried
Today press release was a joke
It means absolutely nothing without a 10Q filing